Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,937 Shares of Stock

Key Points

• Alnylam Pharmaceuticals EVP Pushkal Garg sold 2,937 shares of stock for a total of approximately $1.33 million, reducing his stake by 11.22% to 23,243 shares valued at over $10.5 million.
• The company's stock price reached $456.35, declining by $4.64, while experiencing a recent surge in trading volume with nearly 1 million shares exchanged.
• Alnylam reported $0.32 earnings per share in its last quarterly results, exceeding expectations and demonstrating a 17.3% year-over-year revenue increase to $773.69 million.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Pushkal Garg sold 2,937 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,327,670.85. Following the sale, the executive vice president directly owned 23,243 shares in the company, valued at $10,506,998.15. This trade represents a 11.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Pushkal Garg also recently made the following trade(s):

• On Friday, October 3rd, Pushkal Garg sold 3,022 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56.
• On Tuesday, August 19th, Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $458.41, for a total value of $666,986.55.
• On Monday, August 18th, Pushkal Garg sold 1,396 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.27, for a total value of $632,764.92.

Alnylam Pharmaceuticals Price Performance

ALNY traded down $4.64 during trading on Friday, reaching $456.35. 969,084 shares of the company were exchanged, compared to its average volume of 982,632. The company's 50-day moving average is $439.02 and its two-hundred day moving average is $337.29. The company has a market cap of $59.82 billion, a price-to-earnings ratio of -184.76 and a beta of 0.36. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. During the same quarter last year, the firm posted ($0.13) EPS. The company's revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the company. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals during the 1st quarter worth approximately $27,000. Whipplewood Advisors LLC grew its position in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $30,000. Finally, Elevation Point Wealth Partners LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $37,000. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on ALNY. UBS Group raised their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a report on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and issued a $570.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 2nd. Royal Bank Of Canada raised their price target on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an "outperform" rating in a report on Friday, September 19th. JPMorgan Chase & Co. raised their price target on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Finally, The Goldman Sachs Group increased their price objective on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a "buy" rating in a research report on Tuesday, September 16th. Twenty-four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $439.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.